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Abstract
Extracellular vesicles (EVs) are very promising biomarkers for the diagnosis of various
diseases, including cardiovascular, infectious and neurodegenerative disorders. Of particular
relevance is their importance in cancer liquid biopsy, where they play a key role in the early
detection and monitoring of the tumour. A number of technologies have recently been
developed to improve the performance of current EV detection methods, but a technique that
can provide high resolution, high accuracy and a multiplexing capability for the detection of
several biomarkers in parallel remains a challenge in this field. Here, we demonstrate the
detection of large unilamellar vesicles, which are excellent models of EVs, down to a
concentration <103 EV ml−1 (<10 pM) using a dielectric resonant metasurface. This result
represents an improvement in performance and functionality compared to competing plasmonic
and electrochemical modalities and is due to the strong resonance amplitude and high Q-factor
of our metasurface. We also verify the selectivity of the approach by detecting vesicles that have
been surface-functionalised with a CD9 protein. The ease of integration of our method into a
point-of-care instrument offers a path towards personalised cancer medicine.
Keywords: dielectric metasurface, unilamellar vesicles, exosomes detection,
extracellular vesicles detection, liquid biopsy, photonic biosensor
(Some figures may appear in colour only in the online journal)
1. Introduction
The use of liquid biopsy techniques that do not rely on tissue
samples has seen a significant rise in interest because of a num-
ber of advantages offered for cancer detection and screening.
∗
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Original content from this workmay be used under the terms
of the Creative Commons Attribution 4.0 licence. Any fur-
ther distribution of this work must maintain attribution to the author(s) and the
title of the work, journal citation and DOI.
Liquid biopsy relies on the analysis of cancer biomarkers from
bodily fluids (e.g. blood, urine, saliva), which affords min-
imal invasiveness and avoids pain and possible infections for
patients, thereby overcoming the main disadvantages of tissue
biopsy [1, 2]. This ease of accessibility of cancer biomark-
ers represents a significant improvement for cancer monitoring
and prognosis, because it allows for continuous screening and
prompt detection of the possible recurrence of tumours and
metastasis [3, 4]. Furthermore, many biomarkers are expressed
in bodily fluids even at an early stage of cancer, enabling early
diagnosis and treatment. Despite these evident advantages, the
technique has not yet been adapted as a standard tool in clinical
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oncology, because of the limited sensitivity and specificity of
currently used modalities [5].
A number of cancer biomarkers have already been iden-
tified as possible targets, including circulating tumour cells
(CTCs), nucleic acids (circulating tumour DNA (Deoxyribo-
nucleic acid) and micro-ribonucleic acid (RNA)) and, more
recently, extracellular vesicles (EVs) [6, 7]. The main chal-
lenge with CTCs is their heterogeneity and sparse concentra-
tion, which makes them very difficult to isolate and charac-
terise. The issue with nucleic acids is their short-term stabil-
ity in the bloodstream [8]. In contrast, EVs, and in particular
exosomes, carry the molecular content of their parent cells in
lipid vesicles of about 50–150 nm size, which leads to a much
higher stability [9]. They are abundantly secreted into bodily
fluids and their expression is already observed at an early stage
of cancer. Furthermore, the correlation of EVs with many
other human diseases, including neurodegenerative, infec-
tious and cardiovascular ones, has recently also been verified
[10–12]. Standard analytical methods, such as enzyme-linked
immunosorbent assay (ELISA) andWestern blot, reach a sens-
itivity of order 106 and 108 EV ml−1, respectively, which
is sufficient for detecting EVs in established and metastatic
tumours, but not at the lower concentrations associated, for
example, with early phases of tumour growth and relapse [13],
also requiring a large amount of biological sample.
Other sensing modalities have been recently been intro-
duced to improve the sensitivity. In particular, electrochemical
and optical sensors stand out because they can be integrated
with microfluidic systems that allow EV enrichment and only
require a minimal sample volume [14]. In terms of sensitivity,
electrochemical sensors have reached an impressive perform-
ance down to 103 EV ml−1; their main challenge is the mul-
tiplexing capability, which limits integration to a few sensors
on a single chip [15]. Although electrochemical sensors have
demonstrated high diagnostic accuracy for a specific tumour,
it is challenging to realise a diagnostic tool to predict dif-
ferent types of cancer with a single sensing platform due to
the requirement of detecting a large number of biomarkers in
parallel.
Optical biosensors have been proposed for vesicles detec-
tion [16–18] and have demonstrated to reach similar per-
formance also offering multiplexing capability. In particular,
plasmonic nanostructures have achieved a resolution of about
3 × 103 EV ml−1 with the possibility of integrating tens or
more sensors on the same chip [19]. However, the main issue
of plasmonic configurations arises from the intrinsic losses of
metals, which limit both the Q-factor and the signal-to-noise
ratio of the collected signal, thereby affecting the accuracy of
detecting small changes as already verified for protein detec-
tion [20]. A sensing platform that allows high sensitivity, high
accuracy and a multiplexing capability in a label-free fashion
is therefore still an open challenge.
In order to address these requirements, we have developed
a dielectric metasurface based on a nanohole array geometry,
which optimises the Q-factor, the resonance amplitude and
the surface sensitivity. We have previously verified the sur-
face sensitivity of this structure, which has enabled us to detect
protein biomarkers down to 1 pg ml−1 (<10 fM) [21, 22]. We
now exploit this capability to detect EVs at low concentrations
and verify an LOD < 103 EVml−1 (<10 pM), which improves
on the performance of the plasmonic and electrochemical
sensors, while also offering the accurate detection of small
changes in concentration. We also demonstrate the integration
of the sensors into four separate microfluidic channels in order
to demonstrate the multiplexing capability of the approach.
2. Design and realisation
The nanohole array (figure 1(a)) is realised in oxygen-enriched
hydrogenated amorphous silicon (a-SiOx:H). The array is one
of the family of structures supporting guidedmode resonances.
We chose the quasi-TM mode as most suitable for vesicle
detection [21] because the mode is strongly confined to the
silicon surface in the out-of-plane direction (figure 1(b)). The
evanescent tail of the guidedmode only extends approximately
100 nm into the medium, which leads to a strong interaction
with the surface-bound vesicles that are of similar size. The
use of a-SiOx:H with its relatively high refractive index and
low absorption loss in the near-infrared range (n = 2.4 and
k∼ 5× 10−4 atλ= 700 nm) allows us to obtain highQ-factors
(Q ≈ 400) and strong resonance amplitudes (Rmax ≈ 0.6). We
use a chirped configuration of the nanohole array by spatially
tuning the period in order to simplify the readout system and to
minimise the optical noise [21, 23, 24]. The period of the nan-
ohole array is chirped from an initial value of Λ1 = 410 nm to
Λ2 = 430 nm over a length of 500 µm. Since the Bragg con-
dition for a guided mode resonance sensor (λres = neff × Λ)
defines the resonance position and we use a single wavelength
input, the resonance condition will only be satisfied in the
region of the grating for which the period satisfies the Bragg
condition. The resonance then appears as a bright line in reflec-
tion, whose width depends on the combination of theQ-factor,
the degree of chirp we apply to the period and the bandwidth
of the optical source.
Any change of the effective index due to the binding of the
vesicles corresponds to a spatial shift of the resonance in the
chirped sensor because the Bragg condition will be satisfied
for a different period, because the input wavelength is fixed.
The spatial shift of the resonance allows us to quantify the
effective index change and, therefore, the vesicle concentra-
tion. While the period changes along the length of the grating,
the hole radius r and waveguide thickness t are kept constant
with r = (60 ± 5) nm and t = (120 ± 5) nm. Standard fabric-
ation involving e-beam lithography (Voyager; Raith GmbH)
and reactive ion-etching are used to fabricate the structure, for
details see [18].
We characterise the structure with an optical setup based
on an inverted microscope and excite the resonant mode with
a normally incident collimated beam from a halogen source
(ScienceTech) filtered by a monochromator (ScienceTech)
(figure 2(a)) [20], in order to produce a single wavelength
input. In particular, the monochromator selects a wavelength
with a spectral resolution of 0.7 nm to match the resonance
wavelength of the nanohole array (λ ∼ 680 nm) in the central
region of the chirped grating. The reflected signal is then
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Figure 1. Dielectric metasurface for vesicle detection. (a) SEM micrograph of a nanohole array in a-SiOx:H. (b) Resonant mode
confinement of a transverse magnetic (TM) mode with Λ = 420 nm, t = 120 nm and R = 60 nm. (c) Schematic of the chirped nanohole
array, with the yellow line representing the resonance condition (top). Camera image obtained with the array for an input beam at
λ = 680 nm, corresponding to a Fano-shaped resonance (red curve) in the central area of the nanohole array (bottom). (d) Operation
principle of vesicle sensing with a chirped array with a shift of the initial resonance position (top) to shorter periods (bottom), due to an
increase of the effective index following the binding of vesicles for a fixed operating wavelength. The resonance positions in the camera
image for both cases are shown on the right side, with ∆ as the relative shift following the binding of vesicles.
collected by a camera (Quantalux sCMOS, THORLABS),
which shows the central bright line corresponding to the res-
onance. The change of the resonance position is tracked with
the camera and related to the concentration of the vesicles
(figure 1(d)).
The sensitivity of the chirped configuration is determined
via the spatial shift of the resonance position by exposing the
sensor to different glucose concentrations. The chirped con-
figuration provides a high value of signal-to-noise ratio up to
SNR= 180. The high SNR value can be reached by averaging
multiple Fano-shaped spectra taken along different horizontal
lines (grey lines) of the whole chirped configuration in order
to achieve a single resonant response (dotted lines), as shown
in figure 2(e), which serves to average any spatial variation
due to fabrication tolerances. Moreover, by applying the Fano-
fit on the measured data integrated in the whole sensor area
(continuous lines), it is possible to further decrease the system
noise with an improvement of the accuracy in the resonance
tracking. We find a resonance shift of ∆ = (39 ± 0.24) µm
(camera pixel size is 1.4 µm) for a refractive index change of
(0.011± 1× 10−4) (figure 2(d)), which translates into a sens-
itivity for the chirped sensor of about 3600 µm RIU−1. Due to
the large amplitude of the resonance, the error in determining
the resonance position is very low (σ = 0.24 µm), which leads
to a limit of detection of 7 × 10−5 RIU (figure 2(e)).
3. Sensing of vesicles with dielectric metasurface
3.1. Detection of biotinylated vesicles
In order to evaluate the performance of our structure for the
detection of vesicles, we use synthetic biotinylated vesicles
as a model system; the creation of the vesicles is described
below. We then functionalise the sensor surface with avidin
immobilised on biotinylated bovine serum albumin (BSA).
In this way, we can exploit the strong binding affinity of
the biotin-avidin pair in order to calibrate the sensor and
to determine the limit of detection for the concentration of
vesicles.
The sensors are integrated in a microfluidic system made in
polydimethylsiloxane elastomer (Dow Corning) (figures 2(b)
and (c)). The system consists of four microchannels connec-
ted to a multi-syringe pump (World Precision Instrument)
aligned to the chirped sensors. The mould for the channels
is made in SU-8 (Microchem) and defined by direct ultravi-
olet (UV) laser writing (Kloé Dilase 650). Each channel has
the same width (350 ± 15) µm and thickness (80 ± 5) µm,
and the gap between successive channels is (150 ± 30) µm.
The first step of the surface functionalisation protocol involves
flowing a solution of 0.1 mg ml−1 of biotinylated BSA
mixed with 1 mg ml−1 BSA in each channel. The unbound
molecules are then removed by rinsing the channels with
50 mM Tris buffer (pH 8.0). The functionalisation process
then follows, by flowing 0.1 mg ml−1 avidin solution in
50 mM Tris buffer (pH 8.0) for 20 min, and finally rins-
ing in Tris buffer for 15 min [25]. The surface functional-
isation protocol is described in figure 3(a). Large unilamel-
lar vesicles are prepared in buffer solution (50 mM Tris,
pH 8) via extrusion. Briefly, resuspended lipids are passed
through a polycarbonate membrane filter to force the form-
ation of ∼100 nm sized vesicles with low polydispersity.
Their composition is 99 molar% 1,2-dimyristoyl-sn-glycero-
3-phosphocholine phospholipid (12.5 mg ml−1) (Avanti)
and 1molar% 1-oleoyl-2-(12-biotinyl(aminododecanoyl))-sn-
3
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Figure 2. System configuration and sensitivity of the chirped nanohole array. (a) Optical setup and ((b) and (c)) photograph and schematic
of the optofluidic system. (d) Resonance shift for a bulk refractive index change from n = 1.3329 (water solution) to n = 1.3441 (glucose
solution). (e) Spectra with a Fano-shape fitting for both concentrations with a spatial shift of (39 ± 0.12) µm with ∆n = 0.011 ± 1 × 10−4,
corresponding to a spatial sensitivity of the chirped nanohole array of about 3600 µm RIU−1. The grey lines represent the measured data
along different sections of the chirped grating, while the dotted and continuous lines represent the measured data obtained by the integration
along the whole chirped structures and the correspondent fits, respectively. For reference, the size of the window of 104 µm corresponds to
an equivalent wavelength window of ∆λ = 6.7 nm.
glycero-3-phosphoethanolamine (biotin-PE) (Avanti Polar
Lipids) (0.06 mg ml−1).
The size distribution of the prepared vesicles in buf-
fer solution is evaluated by dynamic light scattering using
a Zetasizer µV molecular size detector (Malvern Instru-
ments Ltd, UK), whereby a mean polydispersity index
<0.3 is observed [25, 27]. When the vesicles are doped
with 0.1 molar% of the fluorescent membrane stain 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlor-
ate, wide-field total internal reflection fluorescence micro-
scopy (λex = 532 nm, λem = 570 nm) is used to quantify the
number and concentration of surface-immobilised vesicles per
25 × 50 µm field of view [27]. Scanning electron microscope
(SEM)micrographs confirm the vesicles have an expected size
of about 100± 20 nm, presenting a spherical and intact shape
without fusing on the surface (figure 2(b)), confirming the pos-
sibility to use them as excellent model for exosomes.
Three different concentrations of vesicles, i.e. 103, 104 and
105 EV ml−1 are prepared in 50 mM TRIS buffer (PH 8.0),
corresponding to 10 pM, 100 pM and 1 nM concentrations,
respectively, and introduced into the microfluidic channels at
20 µl min−1 (figure 3(a)). The binding assay for biotinylated
vesicles in figure 3(d) shows the possibility of detecting ves-
icle concentrations even lower than 103 EV ml−1, given that
the saturation value for 103 EVml−1 is more than twice above
the 3σ noise level; by extrapolating the concentration vs res-
onance shift curve of figure 3(c), we can estimate an LOD of
400 CFUml−1, which presents a clear improvement over other
approaches such as plasmonic structures and electrochemical
detection, both of which have reported LODs > 103 EV ml−1.
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Figure 3. Real-time sensing of vesicle immobilisation via biotin-avidin interactions. (a) Schematic of the immobilisation scheme for
biotinylated vesicles on the surface of the optical sensor using biotin-avidin interaction. The dimensions are not to scale. Created with
BioRender.com (b) SEM micrographs of biotinylated vesicles on the nanohole array. (c) Configuration of chirped nanohole arrays with
multiple parallel channels. (d) Binding assay for different concentrations of biotinylated vesicles with avidin-coated surface, 10 pM (red
curve), 100 pM (green curve) and 1 nM (blue curve) including a control measurement with lipid vesicles without surface functionalisation
(black curve). The measured data (dots) are fitted with the modified Gompertz model (continuous lines) [26]. (e) Histograms of the
resonance shift for different concentrations of functionalised vesicles. The error bars represent the maximum deviation from the average
value for each concentration, with three measurements taken for each concentration. The 3σ value is indicated by the light orange area.
The control experiment, for which the same functionalisa-
tion procedure was used, but flowing a solution with vesicles
without biotin, returns a resonance shift within the noise level,
confirming the strong selectivity of our sensors. By taking
multiple data points for each concentration of vesicles to verify
the reliability of the measurement, we note how the strong res-
onance and correspondingly high SNR (=180) allows us to
track even very small changes of concentrations over a wide
biological range (from a few pM to nM), which is important
for the screening and prognosis of disease.
3.2. Detection of CD9 functionalised vesicles
In order to validate the suitability of the sensing modality
for the detection of exosomes that contain proteins for can-
cer liquid biopsy, we have also functionalised the surface of
the vesicles with the transmembrane protein CD9, which is
one of the most common biomarkers for exosomes [28]. Its
strong expression on a variation of vesicles allows us to use
this protein as useful and versatile marker for quantifying
the presence of vesicles and correlate it to the stage of dis-
ease. CD9 is considered relevant for many types of cancer,
5
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Figure 4. Sensing of vesicles functionalised with CD9. (a) Schematic of the immobilisation scheme for CD9-functionalised vesicles on the
surface of the optical sensor using the α-CD9 antibody. The dimensions are not to scale. (b) Binding assay of CD9-functionalised vesicles
with a concentration of 1 nM (blue curve) and 100 pM (green curve). The control experiments conducted with vesicles functionalised with
CD9 and an unspecific α-IgG antibody (black curve) as well as with vesicles without functionalisation (red curve) confirm a negligible
resonance shift below the 3σ noise level (blue shaded area). The measured data (dots) are fitted with the modified Gompertz model
(continuous lines) [26].
such as pancreatic [29], prostate [30], breast [31] and ovarian
cancer [32].
To improve the binding efficiency between the vesicles
functionalised with CD9 protein and the specific antibody
(α-CD9), the sensor surface is initially coated in
sulfhydryl groups via the salinisation with (3-mercapto-
propyl)trimethoxysilane (MPTS) for 6 h. The thiolated sensor
surface can bind to the maleimide terminated SM(PEG)6,
which presents an N-hydrox-ysuccinimide (NHS) ester group
on the other termini. We use the monolayer of NHS esters in
order to form a covalent bond with free amines on the anti-
body surface. The SM(PEG)6 monolayer is formed during an
overnight process with a 1 mM PEG in Dimethyl Sulfoxide
(DMSO) solution. A rinse in DMSO allows to remove the
excess SM(PEG)6 not bound to MPTS. The functionalisa-
tion protocol is described in detail in [33]. The sensor surface
is then covered with the α-CD9 (Fisher Scientific) antibody
introduced into the sensor channels for 30 min at 20 µl min−1,
followed by casein at the same flow for 30 min and a rinse in
phosphate-buffered-saline (PBS) for another 15min to remove
the excess casein.
The vesicles are immersed in PBS solution with a mixture
of 100 nm phosphatidylcholine (POPC, 8.75 mg ml−1) and
200.8 µM CD9 (EnQuireBio) to functionalise the membrane
surface with CD9 proteins. The vesicles are then purified by
size exclusion chromatography in order to remove any free
CD9 protein in solution not bound on their surface. A schem-
atic of the immobilisation scheme is shown in figure 4(a). The
binding of the CD9-functionalised vesicles is then analysed
similarly for four channels as described for biotinylated ves-
icles (figure 3(a)).
Two different concentrations of CD9-functionalised ves-
icles of concentrations 100 pM (green curve, figure 4(b)) and
1 nM (blue curve, figure 4(b)) respectively, are introduced to
the two sensors with a flow of 20 µl min−1. The other two
sensors are used for control experiments, the first with ves-
icles without attached CD9 protein (control 1, black curve,
figure 4(b)) and the second with CD9-functionalised vesicles
with the sensor surface being covered by the unspecific α-IgG
antibody (control 2, red curve, figure 4(b)). A clear shift of the
resonance is observed with a concentration of 100 pM, con-
firming the ability to detect a vesicle concentration as low as
10 pM (∼103 EV ml−1) or even lower, as already observed
with biotinylated vesicles. The negligible changes observed
for both control experiments provide a clear indication of the
high specificity of our sensors.
4. Discussion and conclusion
Overall, we have introduced a dielectric metasurface for the
detection of EVs and have demonstrated a limit of detection
of LOD < 103 EV ml−1 for such vesicles, which represents
an improvement compared to other techniques, in particular
with respect to the plasmonic counterpart. This advantage is
evidenced by the high sensitivity together with a higher res-
onance amplitude and Q-factor [21], because of negligible
losses in dielectric materials. Moreover, we have verified sim-
ilar performance to another dielectric metasurfaces previously
proposed for EV detection (<10 pM) operating in the near-
infrared region [34], instead we use a complete label-free fash-
ion and work in the visible range, where it is possible to use
low cost sources and detectors.
This high sensitivity, combined with the demonstrated high
rejection of non-specific binding and the ability to detect
small changes in concentration are key requirements for cancer
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detection at an early stage [7, 35]. We have used CD9 as a
surface protein that indicates a range of cancers.We note, how-
ever, that other surface proteins could be used to diagnose spe-
cific types of cancers and to differentiate between metastatic
and non-metastatic tumours, e.g. lung (lipopolysaccharide-
binding proteins) [36] and ovarian (integrin α5β1/AEP com-
plex) [28] cancer that are expressed at even lower concentra-
tions of few ng ml−1. Such concentrations are also accessible
to the detection range of our dielectric metasurface (e.g. a
concentration of 10 pM corresponds to a concentration of
10 ng ml−1 assuming a molar mass of vesicles of 1000 kDa
[37]). Interestingly, the ability to provide high precision exo-
some detection is also emerging as a powerful tool for the
prediction and differentiation of a number of other diseases,
including infectious [12] and neurodegenerative (Alzheimer’s
and Parkinson’s) diseases [38, 39]. In particular, in the context
of neurodegerative diseases, it has been recently suggested that
exosomes are responsible for the spread of toxic β-amyloid
and hyperphosphorylated tau between cells, which represents
the main cause of apoptosis with a consequent neuronal loss in
the early stages of Alzheimer’s disease [40]. Therefore, due to
the important role assumed by exosomal proteins in pathogen-
esis, a prompt and accurate detection of exosome biomarkers
could improve the current limitations in diagnostics of neuro-
degenerative diseases even before clinical signs appear, which
may offer opportunities for early therapeutic intervention.
Although the CD9 protein is the only biomarker considered
in this study, we have already demonstrated the capability to
detect at least four different biomarkers [33], which would
allow an even more accurate diagnosis of the type and stage
of cancer observed.
We have also previously verified the ability of our techno-
logy to achieve a very high sensitivity for protein detection
both in urine and in buffer solutions [33] as well as the possib-
ility to integrate this modality into a low-cost portable instru-
ment [41]. These advantages could enable performing patient-
centric clinical diagnosis and facilitate the widespread use of
point-of-care devices for cancer screening thereby improving
disease prognosis and patient survival.
Data availability statement
The data that support the findings of this study are available
upon reasonable request from the authors.
Acknowledgments
DC and T FK acknowledge financial support by the EPSRC of
the UK (EP/P030017/1). S D Q thanks Alzheimer’s Research
UK (ARUK-RF2019A-001) for support.
ORCID iDs
D Conteduca https://orcid.org/0000-0003-0917-2709
S D Quinn https://orcid.org/0000-0003-3442-4103
T F Krauss https://orcid.org/0000-0003-4367-6601
References
[1] Alix-Panabières C and Pantel K 2021 Liquid biopsy: from
discovery to clinical application Cancer Discov.
11 858–73
[2] Wan J C M, Massie C, Garcia-Corbacho J, Mouliere F,
Brenton J D, Caldas C, Pacey S, Baird R and Rosenfeld N
2017 Liquid biopsies come of age: towards implementation
of circulating tumour DNA Nat. Rev. 17 223–38
[3] Pantel K and Alix-Panabières C 2019 Liquid biopsy and
minimal residual disease—latest advances and implications
for cure Nat. Rev. Clin. Oncol. 16 409–24
[4] Conteduca V et al 2020 Br. J. Cancer 123 982–7
[5] Gorgannezhad L, Umer M, Islam N, Nguyen N-T and
Shiddiky M J A 2018 Circulating tumor DNA and liquid
biopsy: opportunities, challenges, and recent advances in
detection technologies Lab Chip 18 1174–96
[6] Zhou B, Xu K, Zheng X, Chen T, Wang J, Song Y, Shao Y and
Zheng S 2020 Application of exosomes as liquid biopsy in
clinical diagnosis Signal Transduct. Target. Ther. 5 144
[7] Wang W, Luo J and Wang S 2018 Recent progress in isolation
and detection of extracellular vesicles for cancer diagnostics
Adv. Healthcare Mater. 7 1800484
[8] Ko J, Carpenter E and Issadore D 2016 Detection and isolation
of circulating exosomes and microvesicles for cancer
monitoring and diagnostics using micro-/nano-based
devices Analyst 141 450–60
[9] Möller A and Lobb R J 2020 The evolving translational
potential of small extracellular vesicles in cancer Nat. Rev.
Cancer 20 697–709
[10] Fu S, Zhang Y, Li Y, Luo L, Zhao Y and Yao Y 2020
Extracellular vesicles in cardiovascular diseases Cell Death
Discov. 6 68
[11] Lee S, Mankhong S and Kang J-H 2019 Extracellular vesicle
as a source of Alzheimer’s biomarkers: opportunities and
challenges Int. J. Mol. Sci. 20 1728
[12] de Toro J, Herschlik L, Waldner C and Mongini C 2015
Emerging roles of exosomes in normal and pathological
conditions: new insights for diagnosis and therapeutic
applications Front. Immunol. 6 203
[13] Jung H H, Kim J-Y, Lim J E and Im Y-H 2020 Cytokine
profiling in serum-derived exosomes isolated by different
methods Sci. Rep. 10 14069
[14] Im H, Lee K, Weissleder R, Lee H and Castro C M 2017
Novel nanosensing technologies for exosome detection and
profiling Lab Chip 17 2892–8
[15] Hashkavayi A B, Cha B S, Lee E S, Kim S and Park K S 2020
Advances in exosome analysis methods with an emphasis
on electrochemistry Anal. Chem. 92 12733–40
[16] Jahani Y, Arvelo E R, Yesilkoy F, Koshelev K, Cianciaruso C,
de Palma M, Kivshar Y and Altug H 2021 Imaging-based
spectrometer-less optofluidic biosensors based on dielectric
metasurfaces for detecting extracellular vesicles Nat.
Commun. 12 3246
[17] Zhang Q, Loghry H J, Qian J, Kimber M J, Dong L and Lu M
2021 Towards nanovesicle-based disease diagnostics: a
rapid single-step exosome assay within one hour through in
situ immunomagnetic extraction and nanophotonic
label-free detection Lab Chip 21 3541–9
[18] Jackman J A, Linardy E, Yoo D, Seo J, Ng W B, Klemme D J,
Wittenberg N J, Oh S-H and Cho N-J 2016 Plasmonic
nanohole sensor for capturing single virus-like particles
toward virucidal drug evaluation Small 12 1159–66
[19] Im H, Shao H, Park Y I, Peterson V M, Castro C M,
Weissleder R and Lee H 2014 Label-free detection and
molecular profiling of exosomes with a nano-plasmonic
sensor Nat. Biotechnol. 32 490–5
[20] Li X, Soler M, Szydzik C, Khoshmanesh K, Schmidt J,
Coukos G, Mitchell A and Altug H 2018 Label-free
7
J. Opt. 23 (2021) 114002 D Conteduca et al
optofluidic nanobiosensor enables real-time analysis of
single-cell cytokine secretion Small 14 1800698
[21] Conteduca D, Barth I, Pitruzzello G, Reardon C P, Martins E R
and Krauss T F 2021 Dielectric nanohole array metasurface
for high-resolution near-field sensing and imaging Nat.
Commun. 12 3293
[22] Barth I, Conteduca D, Reardon C, Johnson S and Krauss T F
2020 Common-path interferometric label-free protein
sensing with resonant dielectric nanostructures Light Sci.
Appl. 9 96
[23] Triggs G J, Wang Y, Reardon C P, Fischer M, Evans G J O and
Krauss T F 2017 Chirped guided-mode resonance biosensor
Optica 4 229–34
[24] Blanchard-Dionne A-P and Meunier M 2019 Multiperiodic
nanohole array for high-precision sensing Nanophotonics
8 325–9
[25] Dalgarno P A et al 2019 Unveiling the multi-step
solubilization mechanism of submicron size vesicles by
detergents Sci. Rep. 9 12897
[26] Zwietering M H, Jongenburger I, Rombouts F M and Riet K
1990 Modeling of the bacterial growth curve Appl. Environ.
Microbiol. 56 1875–81
[27] Juan-Colás J, Dresser L, Morris K, Lagadou H, Ward R H,
Burns A, Tear S, Johnson S, Leake M C and Quinn S D
2020 The mechanism of vesicle solubilization by the
detergent sodium dodecyl sulfate Langmuir 36 11499–507
[28] Brosseau C, Colas L, Magnan A and Brouard S 2018 CD9
tetraspanin: a new pathway for the regulation of
inflammation? Front. Immunol. 9 2316
[29] Khushman M, Bhardwaj A, Patel G K, Laurini J A, Roveda K,
Tan M C, Patton M C, Singh S, Taylor W and Singh A P
2017 Exosomal markers (CD63 and CD9) expression
pattern using immunohistochemistry in resected malignant
and nonmalignant pancreatic specimens Pancreas 46 782–8
[30] Salvi S et al 2021 Detection and investigation of extracellular
vesicles in serum and urine supernatant of prostate cancer
patients Diagnostics 11 466
[31] Ullah M, Akbar A, Ng N N, Concepcion W and Thakor A S
2019 Mesenchymal stem cells confer chemoresistance in
breast cancer via a CD9 dependent mechanism Oncotarget
10 3435–50
[32] Li X, Tang M, Zhu Q, Wang X, Lin Y and Wang X 2020 The
exosomal integrin α5β1/AEP complex derived from
epithelial ovarian cancer cells promotes peritoneal
metastasis through regulating mesothelial cell proliferation
and migration Cell. Oncol. 43 263–77
[33] Kenaan A, Li K, Barth I, Johnson S, Song J and Krauss T F
2020 Guided mode resonance sensor for the parallel
detection of multiple protein biomarkers in human urine
with high sensitivity Biosens. Bioelectron. 153 112047
[34] Ndao A, Hsu L, Cai W, Ha J, Park J, Contractor R, Lo Y and
Kanté B 2020 Differentiating and quantifying exosome
secretion from a single cell using quasi-bound states in the
continuum Nanophotonics 9 5
[35] Shao H, Im H, Castro C M, Breakefield X, Weissleder R and
Lee H 2018 New technologies for analysis of extracellular
vesicles Chem. Rev. 118 1917–50
[36] Wang N, Song X, Liu L, Niu L, Wang X, Song X and Xie L
2017 Circulating exosomes contain protein biomarkers of
metastatic non-small-cell lung cancer Cancer Sci.
109 1701–9
[37] Burkova E E, Grigoreva A E, Bulgakov D V, Dmitrenok P S,
Vlassov V V, Ryabchikova E I, Sedykh S E and
Nevinsky G A 2019 Extra purified exosomes from human
placenta contain an unpredictable small number of different
major proteins Mol. Sci. 20 2434
[38] Hampel H, O’Bryant S E, Molinuevo J L, Zetterberg H,
Masters C L, Lista S, Kiddle S J, Batrla R and Blennow K
2018 Blood-based biomarkers for Alzheimer disease:
mapping the road to the clinic Nat. Rev. Neurol. 14 639–52
[39] Jiang C et al 2020 Serum neuronal exosomes predict and
differentiate Parkinson’s disease from atypical
Parkinsonism J. Neurol. Neurosurg. Psychiatry 91 7
[40] Malm T, Loppi S and Kanninen K M 2016 Exosomes in
Alzheimer’s disease Neurochem. Int. 97 193–9
[41] Drayton A, Li K, Simmons M, Reardon C and Krauss T F 2020
Performance limitations of resonant refractive index sensors
with low-cost components Opt. Express 28 32239–48
8
